ProShare Advisors
APGE

ProShare Advisors’s Apogee Therapeutics APGE Stock Holding History

ProShare Advisors’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.42M Buy
10,733
+1,847
+21% +$166K ﹤0.01% 732
2026
Q1 		$748K Sell
8,886
-578
-6% -$42K ﹤0.01% 886
2025
Q4 		$714K Buy
9,464
+2,221
+31% +$140K ﹤0.01% 946
2025
Q3 		$288K Sell
7,243
-1,022
-12% -$39K ﹤0.01% 1460
2025
Q2 		$359K Sell
8,265
-1,970
-19% -$74.9K ﹤0.01% 1324
2025
Q1 		$382K Sell
10,235
-2,570
-20% -$99.4K ﹤0.01% 1245
2024
Q4 		$580K Buy
12,805
+2,985
+30% +$152K ﹤0.01% 1185
2024
Q3 		$577K Buy
9,820
+1,504
+18% +$72.1K ﹤0.01% 1062
2024
Q2 		$327K Sell
8,316
-1,722
-17% -$83.6K ﹤0.01% 1227
2024
Q1 		$667K Buy
+10,038
New +$438K ﹤0.01% 932

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

ProShare Advisors's APGE Position: Q2 2026 in Review

ProShare Advisors increased its Apogee Therapeutics (APGE) stake by 21% in Q2 2026, buying an estimated $166K and bringing the position to 10,733 shares worth $1.42M. The position accounts for ﹤0.01% of the portfolio, ranked #732.

ProShare Advisors first reported a position in APGE in Q1 2024 and has held it in 10 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • ProShare Advisors held 10,733 shares of Apogee Therapeutics worth $1.42M as of Q2 2026.
  • ProShare Advisors bought 1,847 Apogee Therapeutics shares in Q2 2026, an estimated $166K.
  • Apogee Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #732 holding.
  • ProShare Advisors first reported a position in Apogee Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.